Charité - Universitätsmedizin Berlin

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology (2021) Skrahina V, Grittner U, Beetz C, Skripuletz T, Juenemann M, Kraemer HH, Hahn K, et al. Journal article Bone Fractures in Children and Young Adults With Type 1 Diabetes: Age Distribution, Fracture Location, and the Role of Glycemic Control (2021) Eckert AJ, Semler O, Schnabel D, Köstner K, Wurm D, Bechtold-Dalla Pozza S, Schaaf K, et al. Journal article Genetic and epigenetic characterization of posterior pituitary tumors (2021) Schmid S, Solomon DA, Perez E, Thieme A, Kleinschmidt-Demasters BK, Giannini C, Reinhardt A, et al. Journal article Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, et al. Journal article A Predictive Model for Progression of CKD to Kidney Failure Based on Routine Laboratory Tests (2021) Zacharias HU, Altenbuchinger M, Schultheiss UT, Raffler J, Kotsis F, Ghasemi S, Ali I, et al. Journal article Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer (2021) Konecny GE, Hendrickson AE, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, et al. Journal article Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021) Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, et al. Conference contribution Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study (2021) Decker T, Fasching P, Nusch A, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, et al. Conference contribution Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115) (2021) Gruenwald V, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, et al. Conference contribution